DMAC
Diamedica·NASDAQ
--
--(--)
--
--(--)
DMAC fundamentals
Diamedica (DMAC) expects to report earnings on Mar 30, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.18 (YoY 0.00%).
Revenue estimate / YoY
0
--
EPS estimate / YoY
-0.18
0.00%
Report date
Mar 30, 2026
DMAC Earnings Call Summary for Q4,2025
- Preeclampsia Breakthrough: DM199 Phase II interim data shows maternal blood pressure reduction without fetal risk, nearing global trial启动.
- Stroke Momentum: 70% enrollment for interim analysis, 61 sites operational.
- Financial Resilience: $9.9M cash, R&D +55% YoY, supporting 2027 operations.
- Regulatory Progress: FDA-approved Canadian trial, alternative tox models in development.
- CKD Opportunity: DM199 shows promise for hypertension in chronic kidney disease.
Earnings
EPS
Revenue
Revenue & Expenses
Key Indicators
Diamedica (DMAC) key financial stats and ratios, covering profitability, financial health, and leverage.
Income Statement
Diamedica (DMAC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Balance Sheet
Diamedica (DMAC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cash Flow
Diamedica (DMAC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Revenue Breakdown
Where does Diamedica (DMAC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Dividend
Track Diamedica (DMAC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is Diamedica's gross profit margin?What guidance did Diamedica's management provide for the next earnings period?What is Diamedica's latest dividend and current dividend yield?What were the key takeaways from Diamedica’s earnings call?Did Diamedica beat or miss consensus estimates last quarter?What factors drove the changes in Diamedica's revenue and profit?What were the key takeaways from Diamedica's earnings call?What does Diamedica do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
